Andrew Strong is an engineer, entrepreneur and lawyer. He’s also the president, CEO and general counsel of Kalon Biotherapeutics, a biotech company created in 2011 by the Texas A&M University System to do contract development and manufacture, of drugs for cancer treatment and vaccines for influenza and other infectious diseases.
“The first thing I did was go out and hire the best people I could find,” said Strong. Three years later, the company has more than 100 employees and is forecasting $20 million in revenue.
